CYP2C9 - Pharmacogenomics test for the administration of Siponimod

The test is based on pharmacogenomics and identifies the metabolic pathway of the medicinal substance Siponimod, which is administered to patients with multiple sclerosis. CYP2C9 test is considered essential to determine candidacy for drug administration and the appropriate dosage before treatment initiation.

Siponimod is contraindicated in patients with a CYP2C9*3/*3 genotype

Contraindications to siponimod include patients homozygous for the CYP2C9*3/*3 genotype. They may have significant arrhythmias or conduction disorders (unless the patient has got a pacemaker) and with myocardial infarction, angina, stroke, decompensated heart failure or class III or IV heart failure.


The test is performed on 1 EDTA vial of blood or saliva sample

If you want to send us your sample, please contact us in order to arrange all procedures.

Αν θέλετε να μας στείλετε το δείγμα σας, επικοινωνήστε μαζί μας προκειμένου να κανονίσουμε όλες τις διαδικασίες.